Selective activity of deguelin identifies therapeutic targets for androgen receptor-positive breast cancer

Genes associated with histopathologic features of triple negative breast tumors predict molecular subtypes

(2016) Kristen S. Purrington et al.   BREAST CANCER RESEARCH AND TREATMENT

An analysis of FDA-approved drugs: natural products and their derivatives

(2016) Eric Patridge et al.   DRUG DISCOVERY TODAY

Deguelin induces the apoptosis of lung cancer cells through regulating a ROS driven Akt pathway

(2015) Huae Xu et al.   Cancer Cell International

High Efficacy of Combination Therapy Using PI3K/AKT Inhibitors with Androgen Deprivation in Prostate Cancer Preclinical Models

(2015) Rute B. Marques et al.   EUROPEAN UROLOGY

Differences in Breast Cancer Stage at Diagnosis and Cancer-Specific Survival by Race and Ethnicity in the United States

(2015) Javaid Iqbal et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Multiple Molecular Subtypes of Triple-Negative Breast Cancer Critically Rely on Androgen Receptor and Respond to Enzalutamide In Vivo

(2015) V. N. Barton et al.   MOLECULAR CANCER THERAPEUTICS

Deguelin Induces Apoptosis by Targeting Both EGFR-Akt and IGF1R-Akt Pathways in Head and Neck Squamous Cell Cancer Cell Lines

(2015) Yuh Baba et al.   Biomed Research International

Long term survival of HER2-positive early breast cancer treated with trastuzumab-based adjuvant regimen: A large cohort study from clinical practice

(2014) Martina Bonifazi et al.   BREAST

New Strategies for Triple-Negative Breast Cancer--Deciphering the Heterogeneity

(2014) I. A. Mayer et al.   CLINICAL CANCER RESEARCH

Outcomes by Tumor Subtype and Treatment Pattern in Women With Small, Node-Negative Breast Cancer: A Multi-Institutional Study

(2014) Ines Vaz-Luis et al.   JOURNAL OF CLINICAL ONCOLOGY

Comparative Proteome Analysis Revealing an 11-Protein Signature for Aggressive Triple-Negative Breast Cancer

(2014) Ning Qing Liu et al.   JNCI-Journal of the National Cancer Institute

US Incidence of Breast Cancer Subtypes Defined by Joint Hormone Receptor and HER2 Status

(2014) Nadia Howlader et al.   JNCI-Journal of the National Cancer Institute

Adjuvant trastuzumab improves survival in early breast cancer

(2014) Vicki Brower   LANCET ONCOLOGY

Epidemiology, biology, and treatment of triple-negative breast cancer in women of African ancestry

(2014) Abenaa M Brewster et al.   LANCET ONCOLOGY

The Long-HER Study: Clinical and Molecular Analysis of Patients with HER2+ Advanced Breast Cancer Who Become Long-Term Survivors with Trastuzumab-Based Therapy

(2014) Angelo Gámez-Pozo et al.   PLoS One

Natural products: A continuing source of novel drug leads

(2013) Gordon M. Cragg et al.   BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS

Identification of Prognosis-Relevant Subgroups in Patients with Chemoresistant Triple-Negative Breast Cancer

(2013) K.-D. Yu et al.   CLINICAL CANCER RESEARCH

Phase II Trial of Bicalutamide in Patients with Androgen Receptor-Positive, Estrogen Receptor-Negative Metastatic Breast Cancer

(2013) A. Gucalp et al.   CLINICAL CANCER RESEARCH

Triple-negative breast cancer

(2013) Kim M. Hirshfield et al.   CURRENT OPINION IN OBSTETRICS & GYNECOLOGY

Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials

(2013)   LANCET

mTORC1 Inhibition Is Required for Sensitivity to PI3K p110  Inhibitors in PIK3CA-Mutant Breast Cancer

(2013) M. Elkabets et al.   Science Translational Medicine

An androgen receptor mutation in the MDA-MB-453 cell line model of molecular apocrine breast cancer compromises receptor activity

(2012) Nicole L Moore et al.   ENDOCRINE-RELATED CANCER

Natural Products As Sources of New Drugs over the 30 Years from 1981 to 2010

(2012) David J. Newman et al.   JOURNAL OF NATURAL PRODUCTS

Age-Specific Incidence of Breast Cancer Subtypes: Understanding the Black–White Crossover

(2012) Christina A. Clarke et al.   JNCI-Journal of the National Cancer Institute

Higher population-based incidence rates of triple-negative breast cancer among young African-American women

(2011) Kathryn C. Amirikia et al.   CANCER

Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies

(2011) Brian D. Lehmann et al.   JOURNAL OF CLINICAL INVESTIGATION

Molecular Stratification of Triple-Negative Breast Cancers

(2011) C. M. Perou   ONCOLOGIST

Triple-negative breast cancer: Molecular features, pathogenesis, treatment and current lines of research

(2010) Ana Bosch et al.   CANCER TREATMENT REVIEWS

Triple-negative/basal-like breast cancer: clinical, pathologic and molecular features

(2010) Ramachandran Venkitaraman   Expert Review of Anticancer Therapy

Natural product scaffolds as leads to drugs

(2009) David J Newman et al.   Future Medicinal Chemistry

Randomized Phase II Study Comparing Two Schedules of Everolimus in Patients With Recurrent/Metastatic Breast Cancer: NCIC Clinical Trials Group IND.163

(2009) Susan L. Ellard et al.   JOURNAL OF CLINICAL ONCOLOGY

Population Differences in Breast Cancer: Survey in Indigenous African Women Reveals Over-Representation of Triple-Negative Breast Cancer

(2009) Dezheng Huo et al.   JOURNAL OF CLINICAL ONCOLOGY

What is triple-negative breast cancer?

(2008) William J. Irvin et al.   EUROPEAN JOURNAL OF CANCER